Cytokinetics Gains Astellas as Partner in Field of Skeletal Muscle Activation
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 7 (Table of Contents)
Published: 11 Jul-2013
DOI: 10.3833/pdr.v2013.i7.1963 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Cytokinetics’ R&D efforts in the field of skeletal muscle activation have attracted the interest of Astellas Pharma, which has gained a global licence to the company’s Phase I drug candidate CK-2127107 for non-neuromuscular indications such as sarcopaenia and cachexia...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS